IDALOPIRDINE

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H19F5N2O
Molecular Weight	398.3697
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of IDALOPIRDINE

Structure Search

SMILES

FC(F)C(F)(F)COC1=CC(CNCCC2=CNC3=C2C=CC(F)=C3)=CC=C1

InChI

InChIKey=YBAWYTYNMZWMMJ-UHFFFAOYSA-N

InChI=1S/C20H19F5N2O/c21-15-4-5-17-14(11-27-18(17)9-15)6-7-26-10-13-2-1-3-16(8-13)28-12-20(24,25)19(22)23/h1-5,8-9,11,19,26-27H,6-7,10,12H2

HIDE SMILES / InChI

Molecular Formula	C20H19F5N2O
Molecular Weight	398.3697
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:22:47 UTC 2023` Edited by `admin` on `Fri Dec 15 15:22:47 UTC 2023`
Record UNII	59WCJ0YNWM
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IDALOPIRDINE

Official Name

English

SGS518

Code

English

LU-AE-58054

Code

English

LY483518

Code

English

LU-AE58054

Code

English

1H-INDOLE-3-ETHANAMINE, 6-FLUORO-N-((3-(2,2,3,3-TETRAFLUOROPROPOXY)PHENYL)METHYL)-

Systematic Name

English

LU AE-58054

Code

English

idalopirdine [INN]

Common Name

English

Idalopirdine [WHO-DD]

Common Name

English

LU AE58054

Code

English

N-(2-(6-FLUORO-1H-INDOL-3-YL)ETHYL)-3-(2,2,3,3-TETRAFLUOROPROPOXY)BENZYLAMINE

Systematic Name

English

SGS-518

Code

English

IDALOPIRDINE [USAN]

Common Name

English

LY-483518

Code

English

Code System Code Type Description

EPA CompTox

DTXSID201026015

Created by admin on Fri Dec 15 15:22:47 UTC 2023 , Edited by admin on Fri Dec 15 15:22:47 UTC 2023

PRIMARY

PUBCHEM

21071390

Created by admin on Fri Dec 15 15:22:47 UTC 2023 , Edited by admin on Fri Dec 15 15:22:47 UTC 2023

PRIMARY

INN

9866

Created by admin on Fri Dec 15 15:22:47 UTC 2023 , Edited by admin on Fri Dec 15 15:22:47 UTC 2023

PRIMARY

SMS_ID

100000174941

Created by admin on Fri Dec 15 15:22:47 UTC 2023 , Edited by admin on Fri Dec 15 15:22:47 UTC 2023

PRIMARY

ChEMBL

CHEMBL3286580

Created by admin on Fri Dec 15 15:22:47 UTC 2023 , Edited by admin on Fri Dec 15 15:22:47 UTC 2023

PRIMARY

CAS

467459-31-0

Created by admin on Fri Dec 15 15:22:47 UTC 2023 , Edited by admin on Fri Dec 15 15:22:47 UTC 2023

PRIMARY

NCI_THESAURUS

C166835

Created by admin on Fri Dec 15 15:22:47 UTC 2023 , Edited by admin on Fri Dec 15 15:22:47 UTC 2023

PRIMARY

DRUG BANK

DB11957

Created by admin on Fri Dec 15 15:22:47 UTC 2023 , Edited by admin on Fri Dec 15 15:22:47 UTC 2023

PRIMARY

USAN

BC-92

Created by admin on Fri Dec 15 15:22:47 UTC 2023 , Edited by admin on Fri Dec 15 15:22:47 UTC 2023

PRIMARY

WIKIPEDIA

Idalopirdine

Created by admin on Fri Dec 15 15:22:47 UTC 2023 , Edited by admin on Fri Dec 15 15:22:47 UTC 2023

PRIMARY

FDA UNII

59WCJ0YNWM

Created by admin on Fri Dec 15 15:22:47 UTC 2023 , Edited by admin on Fri Dec 15 15:22:47 UTC 2023

PRIMARY

Related Record Type Details


					545BT5182Y

IDALOPIRDINE HYDROCHLORIDE

SALT/SOLVATE -> PARENT


					Z3LSI83ND8

5-HYDROXYTRYPTAMINE RECEPTOR 6

TARGET -> INHIBITOR

Comments:

Phase III trials showed weak efficacy as compared to phase II trials, which may be explained by underdosing. Phase II trials evaluated the use of 90 mg daily (30 mg TID) as an adjunct to an acetylcholinesterase inhibitor. Study investigators decided to lower the dose of idalopirdine in phase III trials based on receptor occupancy analysis conducted by PET scan

Related Record Type Details


					59WCJ0YNWM

ACTIVE MOIETY